Susquehanna upgrades Infinity Pharmaceuticals Inc. (Nasdaq: INFI) from Neutral to Positive. Price target $7.

Susquehanna analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE